Profile data is unavailable for this security.
About the company
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
- Revenue in USD (TTM)8.33bn
- Net income in USD714.43m
- Incorporated1989
- Employees41.10k
- LocationICON PLCSouth County Business ParkLEOPARDSTOWN, Dublin 18DUBLIN 00000IrelandIRL
- Phone+353 12912000
- Fax+353 12912700
- Websitehttps://www.iconplc.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine Biosciences, Inc. | 2.12bn | 339.20m | 12.35bn | 1.50k | 36.93 | 4.92 | 33.94 | 5.83 | 3.31 | 3.31 | 20.64 | 24.87 | 0.7163 | 0.9811 | 4.95 | 1,513,929.00 | 11.46 | 9.77 | 13.74 | 12.19 | 98.28 | 98.51 | 16.00 | 14.79 | 4.08 | 6.10 | 0.00 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
| Exact Sciences Corp | 2.61bn | -175.01m | 12.56bn | 6.50k | -- | 3.93 | 327.39 | 4.81 | -0.9607 | -0.9607 | 14.28 | 17.29 | 0.401 | 5.43 | 11.81 | 401,847.80 | -2.69 | -9.71 | -2.95 | -10.60 | 73.19 | 74.10 | -6.70 | -28.21 | 1.98 | -- | 0.4478 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
| Insmed Inc | 328.61m | -802.69m | 12.59bn | 912.00 | -- | 314.54 | -- | 38.31 | -5.40 | -5.40 | 2.22 | 0.2329 | 0.2023 | 0.8789 | 9.22 | 360,312.50 | -49.41 | -40.96 | -63.68 | -46.88 | 77.61 | 77.99 | -244.27 | -212.92 | 2.53 | -14.67 | 0.9687 | -- | 24.39 | 98.78 | -55.66 | -- | -2.15 | -- |
| United Therapeutics Corporation | 2.62bn | 1.07bn | 15.35bn | 1.17k | 15.86 | 2.69 | 13.58 | 5.87 | 21.75 | 21.75 | 53.16 | 128.25 | 0.3904 | 2.43 | 9.29 | 2,240,325.00 | 15.96 | 10.38 | 17.53 | 11.27 | 88.85 | 91.47 | 40.87 | 29.25 | 4.18 | -- | 0.0807 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
| Vaxcyte Inc | 0.00 | -497.19m | 15.51bn | 254.00 | -- | 6.50 | -- | -- | -4.62 | -4.62 | 0.00 | 17.96 | 0.00 | -- | -- | 0.00 | -27.70 | -34.22 | -28.85 | -37.21 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.00 | -- | 107.28 | -- |
| Summit Therapeutics Inc | 0.00 | -161.69m | 19.00bn | 105.00 | -- | 97.36 | -- | -- | -0.2299 | -0.2299 | 0.00 | 0.2693 | 0.00 | -- | -- | 0.00 | -55.83 | -77.32 | -75.71 | -86.35 | -- | -- | -- | -20,989.46 | -- | -51.01 | 0.3389 | -- | -100.00 | -- | -680.54 | -- | -4.84 | -- |
| ICON PLC | 8.33bn | 714.43m | 24.23bn | 41.10k | 34.00 | 2.53 | 18.51 | 2.91 | 8.60 | 8.60 | 100.31 | 115.74 | 0.489 | -- | 3.01 | 202,722.40 | 4.19 | 3.93 | 5.00 | 4.80 | 29.75 | 28.91 | 8.57 | 7.37 | -- | 3.86 | 0.264 | -- | 4.89 | 25.62 | 21.18 | 13.67 | 23.79 | -- |
| Moderna Inc | 5.05bn | -5.87bn | 27.67bn | 5.60k | -- | 2.36 | -- | 5.48 | -15.37 | -15.37 | 13.21 | 30.50 | 0.2689 | 3.12 | 25.57 | 901,785.70 | -31.24 | 20.95 | -36.58 | 29.51 | 65.60 | -- | -116.18 | 32.10 | 3.92 | -- | 0.0469 | 0.00 | -64.45 | 119.28 | -156.37 | -- | 46.22 | -- |
| Alnylam Pharmaceuticals, Inc. | 2.34bn | -72.94m | 35.24bn | 2.10k | -- | -- | -- | 15.03 | -0.6285 | -0.6285 | 18.39 | -0.024 | 0.6326 | 3.31 | 158.02 | 1,116,384.00 | -1.97 | -26.56 | -2.62 | -32.77 | 87.00 | 83.66 | -3.11 | -94.26 | 2.93 | 0.6753 | 1.00 | -- | 76.23 | 89.45 | 61.08 | -- | -13.29 | -- |
| Holder | Shares | % Held |
|---|---|---|
| WCM Investment Management LLCas of 30 Jun 2024 | 6.67m | 8.06% |
| Massachusetts Financial Services Co.as of 30 Jun 2024 | 5.00m | 6.04% |
| Ninety One UK Ltd.as of 30 Jun 2024 | 2.68m | 3.23% |
| Boston Partners Global Investors, Inc.as of 30 Jun 2024 | 2.62m | 3.16% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 2024 | 2.62m | 3.16% |
| Lazard Asset Management LLCas of 30 Jun 2024 | 2.45m | 2.96% |
| Wellington Management Co. LLPas of 30 Jun 2024 | 2.17m | 2.63% |
| Capital Research & Management Co. (Global Investors)as of 30 Jun 2024 | 1.90m | 2.29% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 1.76m | 2.13% |
| ClearBridge Investments LLCas of 30 Jun 2024 | 1.51m | 1.82% |
